Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-
phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for …

Acute leukemia is characterized by clonal heterogeneity that contributes to poor drug
responses in patients. Despite treatment advances, the occurrence of relapse remains a …

Leukemia can arise at various stages of the hematopoietic differentiation hierarchy, but the
impact of developmental arrest on drug sensitivity is unclear. Applying network-based …

Summary BCR:: ABL1-independent pathways contribute to primary resistance to tyrosine
kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in …

Acute megakaryoblastic leukemia (AMKL) is a rare, developmentally restricted, and highly
lethal cancer of early childhood. The paucity and hypocellularity (due to myelofibrosis) of …

Even though morphological signs of differentiation have a minimal impact on survival after
intensive cytotoxic therapy for acute myeloid leukemia (AML), monocytic AML cell …

Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has
proved a highly challenging hurdle, despite several decades of concerted clinical trial effort …

Simple Summary Venetoclax–azacitidine is a new standard for elderly or unfit acute myeloid
leukemia patients. Nevertheless, resistance remains a matter of concern. The main genetic …

The treatment of acute myeloid leukemia (AML) has historically relied on cytotoxic
chemotherapy, but modern understanding of AML biology has paved the way for new …

Acute megakaryoblastic leukemia (AMKL) is a rare subtype of acute myeloid leukemia
(AML) in which leukemic blasts have megakaryocytic features. AMKL makes up 4%–15% of …